Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study.

Trp and Tyr(171)-->Stop were tested by PCR-RFLP. There was a higher prevalence of LPL DN genotype (19% vs.12%, p=0.03) and a higher frequency of the N allele (11% vs. 7%) among subjects with MI when compared to controls, with an odds ratio of MI for carriers of 9N allele of 2.46 (95% CI=1.79-3.39, p<0.0001). This association was present in men and women, in non-smokers and in hypertensive patients. A logistic regression model including gender, duration of diabetes, systolic blood pressure, HDL-C, left ventricle hypertrophy and D9N polymorphism showed that the latter still remained significantly associated with MI (OR=1.50, 95% CI=1.02-2.25, p=0.049). These findings suggest that D9N polymorphism can be a useful risk marker for myocardial infarction and that further potential candidate genes should be screened for exploratory analysis and for future therapeutic intervention in diabetes. -->
Contributed Indexing: Investigator: L Introcaso; AP Filomeno; LF Miranda; M Scartezini; RR Rea; MG Bittencourt; LC Bodanese; EH Moriguchi; IB Cruz; JF Saraiva; MH Aguiar; TR Bonfiglioli; AD Souza; LA Souza; KP Torres; EP Silva; L Zagury; V Ellinger; PC Jardim; EA Costa; S Rego; CM Feio; LH Tacito; DR Souza; AC Pires; A Forti; AL Ramos; ME Magalhaes; MC Izar; WG Relvas; AR Chacra; SD Atala; MC Bertolami; A Faludi; Y Nakamura; AA Loures-Vale; IF Almeida; MA Barros; JM Filho; M Veloso; HT Xavier; AC Carvalho; JR Tavares; R Lyra; CA Botelho; MJ Coutinho; R Povoa; MT Bombig; D Argamanijan; CI Brasil; A Guimaraes; AM Ladeia; A Hiltner; MC Carvalho; JP Novazzi; N Kasinski; A Afiune; AG Khoure; TL Martinez; RD Santos; AP Chacra; W Salgado Filho; JC Nicolau; LA Cesar; FA Borges; DR Pomaro; CF Salari; EF Sousa; A Catani; T Helfenstein; SS Ihara; AO Santos; ME Colovati; MI Fonseca; LE Pinto; IE Lopes; L Queiroz; SC Fischer; SW Han
Substance Nomenclature: 0 (Lipids)
EC 3.1.1.34 (Lipoprotein Lipase)
Entry Date(s): Date Created: 20081001 Date Completed: 20090805 Latest Revision: 20090504
Update Code: 20221213
DOI: 10.1016/j.atherosclerosis.2008.08.006
PMID: 18823627
Autor: Izar MC; Cardiology Division, Department of Medicine, Rua Pedro de Toledo 276, São Paulo, SP, Brazil. mcoizar@terra.com.br, Helfenstein T, Ihara SS, Relvas WG, Santos AO, Fischer SC, Pinto LE, Lopes IE, Pomaro DR, Fonseca MI, Bodanese LC, Moriguchi EH, Saraiva JF, Introcaso L, Souza AD, Scartezini M, Torres KP, Zagury L, Jardim PC, Costa EA, Tacito LH, Forti A, Magalhaes ME, Chacra AR, Bertolami MC, Loures-Vale AA, Barros MA, Xavier HT, Lyra R, Argamanijan D, Guimaraes A, Novazzi JP, Kasinski N, Afiune A, Martinez TL, Santos RD, Nicolau JC, Cesar LA, Povoa RM, Carvalho AC, Han SW, Fonseca FA
Jazyk: angličtina
Zdroj: Atherosclerosis [Atherosclerosis] 2009 May; Vol. 204 (1), pp. 165-70. Date of Electronic Publication: 2008 Aug 14.
DOI: 10.1016/j.atherosclerosis.2008.08.006
Abstrakt: The association of polymorphisms affecting lipid metabolism with the risk of myocardial infarction (MI) in type 2 diabetes mellitus was investigated. The Genetics, Outcomes and Lipids in type 2 Diabetes (GOLD) Study is a prospective, multicenter study, conducted on 990 patients presenting diabetes and MI (n=386), or diabetes without previous manifestation of stroke, peripheral or coronary arterial disease (n=604), recruited from 27 institutions in Brazil. APO A1 (A/G -75 and C/T +83) and APO C3 (C/G 3'UTR) non-coding sequences, CETP (Taq 1B), LPL (D9N), APO E (epsilon2, epsilon3, epsilon4,), PON-1 (Q192R), and two LCAT variants Arg(147)-->Trp and Tyr(171)-->Stop were tested by PCR-RFLP. There was a higher prevalence of LPL DN genotype (19% vs.12%, p=0.03) and a higher frequency of the N allele (11% vs. 7%) among subjects with MI when compared to controls, with an odds ratio of MI for carriers of 9N allele of 2.46 (95% CI=1.79-3.39, p<0.0001). This association was present in men and women, in non-smokers and in hypertensive patients. A logistic regression model including gender, duration of diabetes, systolic blood pressure, HDL-C, left ventricle hypertrophy and D9N polymorphism showed that the latter still remained significantly associated with MI (OR=1.50, 95% CI=1.02-2.25, p=0.049). These findings suggest that D9N polymorphism can be a useful risk marker for myocardial infarction and that further potential candidate genes should be screened for exploratory analysis and for future therapeutic intervention in diabetes.
Databáze: MEDLINE